Published in Lancet on May 26, 2010
Substance Use Disorders in HIV People of Cameroon | NCT02356185
Mater-Bronx Rapid HIV Testing Project. (M-BRiHT) | NCT01778374
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84
The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis (2011) 16.88
Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis (2011) 10.96
Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med (2011) 6.79
The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet (2011) 5.87
Successes and challenges of HIV prevention in men who have sex with men. Lancet (2012) 4.94
Community-based intervention to increase HIV testing and case detection in people aged 16-32 years in Tanzania, Zimbabwe, and Thailand (NIMH Project Accept, HPTN 043): a randomised study. Lancet Infect Dis (2011) 4.72
HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med (2012) 4.08
Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscordant couples. AIDS (2011) 3.61
HIV-1 treatment as prevention: the good, the bad, and the challenges. Curr Opin HIV AIDS (2011) 3.39
Have the explosive HIV epidemics in sub-Saharan Africa been driven by higher community viral load? AIDS (2013) 3.36
Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention. PLoS One (2011) 3.27
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med (2013) 3.24
Effect of community-based voluntary counselling and testing on HIV incidence and social and behavioural outcomes (NIMH Project Accept; HPTN 043): a cluster-randomised trial. Lancet Glob Health (2014) 3.15
Modelling HIV epidemics in the antiretroviral era: the UNAIDS Estimation and Projection package 2009. Sex Transm Infect (2010) 3.14
Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med (2013) 3.10
Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. J Infect Dis (2012) 3.06
The contribution of HIV-discordant relationships to new HIV infections in Rakai, Uganda. AIDS (2011) 2.94
Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med (2011) 2.76
Combination HIV prevention: significance, challenges, and opportunities. Curr HIV/AIDS Rep (2011) 2.72
Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clin Trials (2012) 2.71
Universal testing and treatment as an HIV prevention strategy: research questions and methods. Curr HIV Res (2011) 2.60
Increased HIV incidence in men who have sex with men despite high levels of ART-induced viral suppression: analysis of an extensively documented epidemic. PLoS One (2013) 2.55
Dramatic decline in the HIV-1 RNA level over calendar time in a large urban HIV practice. Clin Infect Dis (2011) 2.49
Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050. PLoS One (2012) 2.39
Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa. PLoS One (2010) 2.30
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA (2016) 2.23
The effect of expanded antiretroviral treatment strategies on the HIV epidemic among men who have sex with men in San Francisco. Clin Infect Dis (2011) 2.20
Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the "HIV Treatment as Prevention" experience in a Canadian setting. PLoS One (2014) 2.20
What primary care providers need to know about preexposure prophylaxis for HIV prevention: a narrative review. Ann Intern Med (2012) 2.19
Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis. Lancet Infect Dis (2013) 2.18
Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria. AIDS (2013) 2.17
Antiretroviral therapy for the prevention of HIV transmission: what will it take? Clin Infect Dis (2014) 2.14
Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples. PLoS Med (2012) 2.06
Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial. Lancet Infect Dis (2014) 2.05
Extra-couple HIV transmission in sub-Saharan Africa: a mathematical modelling study of survey data. Lancet (2013) 2.03
High HIV testing uptake and linkage to care in a novel program of home-based HIV counseling and testing with facilitated referral in KwaZulu-Natal, South Africa. J Acquir Immune Defic Syndr (2013) 1.97
HIV treatment as prevention and HPTN 052. Curr Opin HIV AIDS (2012) 1.97
First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy. PLoS One (2011) 1.84
HIV-1 prevention for HIV-1 serodiscordant couples. Curr HIV/AIDS Rep (2012) 1.83
Systematic review of HIV transmission between heterosexual serodiscordant couples where the HIV-positive partner is fully suppressed on antiretroviral therapy. PLoS One (2013) 1.79
Test-and-treat in Los Angeles: a mathematical model of the effects of test-and-treat for the population of men who have sex with men in Los Angeles County. Clin Infect Dis (2013) 1.77
Cost-effectiveness of community-based strategies to strengthen the continuum of HIV care in rural South Africa: a health economic modelling analysis. Lancet HIV (2015) 1.77
HIV treatment as prevention: debate and commentary--will early infection compromise treatment-as-prevention strategies? PLoS Med (2012) 1.76
Antiviral agents and HIV prevention: controversies, conflicts, and consensus. AIDS (2012) 1.73
Elimination of HIV in South Africa through expanded access to antiretroviral therapy: a model comparison study. PLoS Med (2013) 1.73
Evaluating the cost-effectiveness of combination antiretroviral therapy for the prevention of mother-to-child transmission of HIV in Uganda. Bull World Health Organ (2012) 1.72
The Epidemiologic and Economic Impact of Improving HIV Testing, Linkage, and Retention in Care in the United States. Clin Infect Dis (2015) 1.69
The impact of the new WHO antiretroviral treatment guidelines on HIV epidemic dynamics and cost in South Africa. PLoS One (2011) 1.67
HPTN 071 (PopART): a cluster-randomized trial of the population impact of an HIV combination prevention intervention including universal testing and treatment: mathematical model. PLoS One (2014) 1.66
HIV treatment as prevention: models, data, and questions--towards evidence-based decision-making. PLoS Med (2012) 1.62
Highly active antiretroviral therapy does not completely suppress HIV in semen of sexually active HIV-infected men who have sex with men. AIDS (2012) 1.56
Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev (2013) 1.56
An empiric risk scoring tool for identifying high-risk heterosexual HIV-1-serodiscordant couples for targeted HIV-1 prevention. J Acquir Immune Defic Syndr (2013) 1.55
The impact of antiretroviral treatment on the age composition of the HIV epidemic in sub-Saharan Africa. AIDS (2012) 1.55
HIV treatment as prevention: the utility and limitations of ecological observation. PLoS Med (2012) 1.55
Heterosexual HIV-1 infectiousness and antiretroviral use: systematic review of prospective studies of discordant couples. Epidemiology (2013) 1.54
Behaviors of recently HIV-infected men who have sex with men in the year postdiagnosis: effects of drug use and partner types. J Acquir Immune Defic Syndr (2011) 1.54
Shedding of HIV and human herpesviruses in the semen of effectively treated HIV-1-infected men who have sex with men. Clin Infect Dis (2013) 1.53
Antiretrovirals and safer conception for HIV-serodiscordant couples. Curr Opin HIV AIDS (2012) 1.51
Missed opportunities for HIV testing and late-stage diagnosis among HIV-infected patients in Uganda. PLoS One (2011) 1.50
Reproductive decision-making and periconception practices among HIV-positive men and women attending HIV services in Durban, South Africa. AIDS Behav (2013) 1.50
A mathematical model of comprehensive test-and-treat services and HIV incidence among men who have sex with men in the United States. PLoS One (2012) 1.50
Use of antiretrovirals for HIV prevention: what do we know and what don't we know? Curr HIV/AIDS Rep (2013) 1.49
Enrollment in HIV Care Two Years after HIV Diagnosis in the Kingdom of Swaziland: An Evaluation of a National Program of New Linkage Procedures. PLoS One (2016) 1.42
Unreported antiretroviral use by HIV-1-infected participants enrolling in a prospective research study. J Acquir Immune Defic Syndr (2014) 1.40
The role of coinfections in HIV epidemic trajectory and positive prevention: a systematic review and meta-analysis. AIDS (2011) 1.38
Ageing with HIV in South Africa. AIDS (2011) 1.37
Combination prevention: new hope for stopping the epidemic. Curr HIV/AIDS Rep (2013) 1.36
Systemic and topical drugs for the prevention of HIV infection: antiretroviral pre-exposure prophylaxis. Annu Rev Med (2012) 1.36
Modeling the impact on the HIV epidemic of treating discordant couples with antiretrovirals to prevent transmission. AIDS (2011) 1.36
The impact of anticipated HIV stigma on delays in HIV testing behaviors: findings from a community-based sample of men who have sex with men and transgender women in New York City. AIDS Patient Care STDS (2013) 1.34
Understanding the potential impact of a combination HIV prevention intervention in a hyper-endemic community. PLoS One (2013) 1.26
Resurgence of HIV infection among men who have sex with men in Switzerland: mathematical modelling study. PLoS One (2012) 1.25
Antiretroviral therapy as HIV prevention: status and prospects. Am J Public Health (2010) 1.25
Household-based HIV counseling and testing as a platform for referral to HIV care and medical male circumcision in Uganda: a pilot evaluation. PLoS One (2012) 1.24
Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003-2010. PLoS One (2012) 1.24
Preexposure prophylaxis for HIV prevention. Curr HIV/AIDS Rep (2011) 1.24
Can combination prevention strategies reduce HIV transmission in generalized epidemic settings in Africa? The HPTN 071 (PopART) study plan in South Africa and Zambia. J Acquir Immune Defic Syndr (2013) 1.23
Antiretroviral adherence and development of drug resistance are the strongest predictors of genital HIV-1 shedding among women initiating treatment. J Infect Dis (2010) 1.22
Does ART prevent HIV transmission among MSM? AIDS (2012) 1.20
Botswana's progress toward achieving the 2020 UNAIDS 90-90-90 antiretroviral therapy and virological suppression goals: a population-based survey. Lancet HIV (2016) 1.20
Cost-effectiveness of provider-based HIV partner notification in urban Malawi. Health Policy Plan (2013) 1.20
Antiretroviral treatment scale-up among persons living with HIV in Kenya: results from a nationally representative survey. J Acquir Immune Defic Syndr (2014) 1.19
Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial. AIDS (2013) 1.19
Factors associated with presentation to care with advanced HIV disease in Brussels and Northern France: 1997-2007. BMC Infect Dis (2011) 1.18
Attitudes of people in the UK with HIV who Are Antiretroviral (ART) Naïve to starting ART at high CD4 counts for potential health benefit or to prevent HIV transmission. PLoS One (2014) 1.17
HIV drugs for treatment, and for prevention. Lancet (2010) 1.17
Group motivational interviewing to promote adherence to antiretroviral medications and risk reduction behaviors in HIV infected women. AIDS Behav (2011) 1.17
Late entry into HIV care: estimated impact on AIDS mortality rates in Brazil, 2003-2006. PLoS One (2011) 1.15
Integrated behavioral intervention to improve HIV/AIDS treatment adherence and reduce HIV transmission. Am J Public Health (2011) 1.14
Why the proportion of transmission during early-stage HIV infection does not predict the long-term impact of treatment on HIV incidence. Proc Natl Acad Sci U S A (2014) 1.13
Reproductive counseling by clinic healthcare workers in Durban, South Africa: perspectives from HIV-infected men and women reporting serodiscordant partners. Infect Dis Obstet Gynecol (2012) 1.13
Projecting the benefits of antiretroviral therapy for HIV prevention: the impact of population mobility and linkage to care. J Infect Dis (2012) 1.12
Translation of biomedical prevention strategies for HIV: prospects and pitfalls. J Acquir Immune Defic Syndr (2013) 1.12
Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med (2000) 41.18
Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet (2008) 36.01
Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med (2010) 12.08
Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS (2009) 11.62
Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS (2006) 9.45
Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol (1988) 8.09
Relation between HIV viral load and infectiousness: a model-based analysis. Lancet (2008) 5.74
Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study. AIDS (2000) 4.91
Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding. AIDS (2007) 4.74
Treatment to prevent transmission of HIV-1. Clin Infect Dis (2010) 4.54
Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet (2010) 4.23
HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA (2001) 2.95
Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression. AIDS (2008) 2.91
Antiretroviral therapy and sexual behavior: a comparative study between antiretroviral- naive and -experienced patients at an urban HIV/AIDS care and research center in Kampala, Uganda. AIDS Patient Care STDS (2005) 2.48
Changes in risk behavior among HIV-positive patients during their first year of antiretroviral therapy in Cape Town South Africa. AIDS Behav (2008) 2.45
Safer sexual behaviors after 12 months of antiretroviral treatment in Mombasa, Kenya: a prospective cohort. AIDS Patient Care STDS (2008) 2.28
Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma. AIDS (2008) 2.27
Association of initial CD4 cell count and viral load with response to highly active antiretroviral therapy. JAMA (2000) 2.25
The relationship between HAART use and sexual activity among HIV-positive women of reproductive age in Brazil, South Africa, and Uganda. AIDS Care (2008) 2.03
Quantifying HIV for monitoring antiretroviral therapy in resource-poor settings. J Infect Dis (2010) 1.80
Can perinatal HIV infection be eliminated in the United States? JAMA (1999) 1.46
HIV treatment, injection drug use, and illicit drug policies. Lancet (2007) 1.42
When to start antiretroviral therapy in adults in low- and middle-income countries: science and practice. Curr Opin HIV AIDS (2010) 1.33
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84
Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med (2010) 12.08
Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis (2011) 10.96
Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet (2007) 7.22
Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med (2006) 5.73
Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet (2010) 5.41
Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med (2011) 5.21
Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis (2007) 4.52
A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis (2003) 4.49
Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study. Lancet HIV (2015) 4.33
Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet (2010) 4.23
Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis (2007) 4.12
Substance use and sexual risk: a participant- and episode-level analysis among a cohort of men who have sex with men. Am J Epidemiol (2004) 4.03
Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med (2005) 3.96
Regional differences in prevalence of HIV-1 discordance in Africa and enrollment of HIV-1 discordant couples into an HIV-1 prevention trial. PLoS One (2008) 3.94
Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis (2005) 3.91
Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS One (2009) 3.66
Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscordant couples. AIDS (2011) 3.61
What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples. J Acquir Immune Defic Syndr (2012) 3.44
HIV-1 viral load assays for resource-limited settings. PLoS Med (2006) 3.30
Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load. J Virol (2004) 3.28
Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention. PLoS One (2011) 3.27
Association between Mycoplasma genitalium and acute endometritis. Lancet (2002) 3.27
Cohort Profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts. Int J Epidemiol (2005) 3.19
Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med (2010) 3.14
Targeted PCR for detection of vaginal bacteria associated with bacterial vaginosis. J Clin Microbiol (2007) 3.10
High HIV prevalence among men who have sex with men in Soweto, South Africa: results from the Soweto Men's Study. AIDS Behav (2009) 3.06
Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. J Infect Dis (2012) 3.06
Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS One (2008) 3.05
HIV, syphilis and heterosexual bridging among Peruvian men who have sex with men. AIDS (2002) 3.03
Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. AIDS (2009) 2.97
Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood (2009) 2.92
The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLoS One (2012) 2.88
The Medical Education Partnership Initiative: PEPFAR's effort to boost health worker education to strengthen health systems. Health Aff (Millwood) (2012) 2.84
Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis (2008) 2.77
Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med (2011) 2.76
Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med (2011) 2.76
Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen. Emerg Infect Dis (2002) 2.76
Combination HIV prevention: significance, challenges, and opportunities. Curr HIV/AIDS Rep (2011) 2.72
HIV-1, sexually transmitted infections, and sexual behavior trends among men who have sex with men in Lima, Peru. J Acquir Immune Defic Syndr (2007) 2.71
Periconception pre-exposure prophylaxis to prevent HIV transmission: benefits, risks, and challenges to implementation. AIDS (2010) 2.70
Vaginal washing and increased risk of HIV-1 acquisition among African women: a 10-year prospective study. AIDS (2006) 2.67
Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women. Clin Infect Dis (2006) 2.65
Temporal variability of human vaginal bacteria and relationship with bacterial vaginosis. PLoS One (2010) 2.62
HIV/AIDS stigma and refusal of HIV testing among pregnant women in rural Kenya: results from the MAMAS Study. AIDS Behav (2011) 2.59
Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One (2010) 2.48
Injectable contraceptive use and genital ulcer disease during the early phase of HIV-1 infection increase plasma virus load in women. J Infect Dis (2004) 2.47
HIV incidence determination in the United States: a multiassay approach. J Infect Dis (2012) 2.47
Xpert(®) MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope? Expert Rev Mol Diagn (2010) 2.47
Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr (2010) 2.46
Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med (2013) 2.44
Management of herpes simplex virus type 2 infection in HIV type 1-infected persons. Clin Infect Dis (2006) 2.43
HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr (2014) 2.43
CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa. PLoS One (2009) 2.37
Viral linkage in HIV-1 seroconverters and their partners in an HIV-1 prevention clinical trial. PLoS One (2011) 2.36
Sexual risk behaviors and implications for secondary HIV transmission during and after HIV seroconversion. AIDS (2002) 2.33
Human immunodeficiency virus type 1 (HIV-1) diversity at time of infection is not restricted to certain risk groups or specific HIV-1 subtypes. J Virol (2004) 2.33
Conceptual framework for understanding the bidirectional links between food insecurity and HIV/AIDS. Am J Clin Nutr (2011) 2.32